Showing results (41-50 of 96) with videos related to
Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|March 2, 2005
A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervixJennifer J Knox, Lillian L Siu, Eric Chen, et al.Cancer Chemotherapy and Pharmacology|February 22, 2012
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancerDaniel J Renouf, Stephen Welch, Malcolm J Moore, et al.American Journal of Clinical Oncology|June 7, 2006
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 casesPaula N Fishman, Gregory R Pond, Malcolm J Moore, et al.Investigational New Drugs|April 29, 2011
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancerDaniel J Renouf, Patricia A Tang, Pierre Major, et al.Cancer Chemotherapy and Pharmacology|April 6, 2005
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumoursLyly H Lê, Malcolm J Moore, Lillian L Siu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2014
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine TumorsTimothy J Hobday, Rui Qin, Diane Reidy-Lagunes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerEric Van Cutsem, Walter L Vervenne, Jaafar Bennouna, et al.Investigational New Drugs|March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumSrikala S Sridhar, Eric Winquist, Andrea Eisen, et al.Clinical Genitourinary Cancer|January 22, 2013
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinomaBenjamin L Maughan, Neeraj Agarwal, Syed A Hussain, et al.The Oncologist|March 29, 2014
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancerRocio Garcia-Carbonero, Fernando Rivera, Joan Maurel, et al.Pageof 10